Plasma plasminogen activator inhibitor 1, insulin resistance and android obesity

Biomedicine and Pharmacotherapy

Volumn 53, Issue 10, 1999, Pages 455-461

  Bastard, J P ^a   Pieroni L ^b  

^a HÔPITAL TENON   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Adipose tissue; Insulin resistance; Obesity; Plasminogen activator inhibitor 1

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ATHEROSCLEROTIC PLAQUE; CORONARY RISK; DIABETES MELLITUS; FIBRINOLYSIS; HUMAN; INSULIN RESISTANCE; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOSIS;

EID: 0033397387     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(00)88103-2     Document Type: Article

References (98)

1. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line HepG2. Thromb Haemost 1988; 60 : 491-4.
2. Alessi MC, Juhan-Vague I. Endothelium, thrombosis and fibrinolysis. Rev Prat 1997; 47 : 2227-31.
3. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46 : 860-7.
4. Almer LO, Ohlin H. Elevated levels of the rapid inhibitor of plasminogen activator inhibitor (t-Pai) in acute myocardial infarction. Thomb Res 1987; 47 : 335-9.
5. Anfosso F, Chomiki N, Alessi MC, Vague P, Juhan-Vague I. Plasminogen activator inhibitor 1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin. J Clin Invest 1993; 91 : 2185-93.
6. Asplund-Carlson A, Hamsten A, Wiman B, Carlson LA. Relationship between plasma plasminogen activator inhibitor 1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: Studies in randomly selected normo- and hyper-triglyceridaemic men. Diabetologia 1993; 36 : 817-25.
7. Barret-Connor EL. Obesity, atherosclerosis, and coronary disease. Ann Intern Med 1985; 103 : 1010-9.
8. Bastard JP, Bruckert E, Robert JJ, Ankri A, Grimaldi A, Jardel C, et al. Are free fatty acids related to plasma plasminogen activator inhibitor 1 in android obesity? Int J Obesity 1995; 19 : 836-8.
9. Bastard JP, Bruckert E, Porquet D, Ankri A, Jardel C, Delattre J, et al. Evidence for a relationship between plasminogen activator inhibitor-1 and gamma glutamyl transferase. Thromb Res 1996; 81 : 271-5.
10. Bastard JP, Bruckert E, Giral P, Beucler I, Ankri A, Hainque B, et al. Plasminogen activator inhibitor-1 antigen levels are related to gamma glutamyl transferase in hyperlipidaemic women. Nutr Metab Cardiovasc Dis 1997; 7 : 371-5.
11. Bastard JP, Vidal H, Jardel C, Bruckert E, Robin D, Vallier P, et al. Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 gene during very low calorie diet in obese subjects. Int J Obesity 1999; in press.
12. Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev 1985; 6 : 45-86.
13. Bini A, Kudryk BJ. Fibrin and its derivatives in the normal and diseased vessel wall. Ann NY Acad Sci 1992; 667 : 112-26.
14. Björntorp P. Liver triglycerides and metabolism. Int J Obesity 1995; 19 : 839-40.
15. Bruckert E, Ankri A, Giral P, Turpin G. Relationship between plasma plasminogen activator inhibitor-1 and hepatic enzyme concentrations in hyperlipidemic patients. Thromb Haemost 1994; 72 : 434-7.
16. Brassard HE, Gevers-Leuven JA, Krans HMJ, Meijer P, Buytenhek R, Kluft C. Non-esterified fatty acids are related to hypofibrinolysis in type 2 diabetes mellitus. Fibrinolysis 1994; 8 Suppl 2 : 25-7.
17. Calles-Escandon J, Ballor D, Harvey-Berino J, Ades P, Tracy R, Sobel B. Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction. Am J Clin Nutr 1996; 64 : 7-11.
18. Cigolini M, Targher G, Seidell JC, Tonoli M, Schiavon R, Agostino G, et al. Relationships of blood pressure to fibrinolysis: Influence of anthropometry, metabolic profile and behavioural variables. J Hypertens 1995; 13 : 659-66.
19. Cigolini M, Targher G, Agostino G, Tonoli M, Muggeo M, De Sandre G. Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men: Role of the metabolic syndrome. Thromb Haemost 1996; 76 : 69-73.
20. Cigolini M, Targher G, Bergamo Andreis IA, Tonoli M, Agostino G, De Sandre G. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vase Biol 1996; 16 : 368-74.
21. Davies MJ, Thomas A. Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death. N England J Med 1984; 310 : 1137-40.
22. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor 1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb Vasc Biol 1991; 11 : 183-90.
23. Dawson S, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor 1 (PAI-1) gene respond differently to interleukin-1 in Hep G2 cells. J Biol Chem 1993; 268 : 10739-45.
24. De Fronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237 : E214-23.
25. Doggen CJM, Bertina RM, Mager Cats V, Reistma PH, Rosendall FR. The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction. Thromb Haemost 1999; 82 : 115-20.
26. Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL. Lipoprotein (a) regulates plasminogen activator inhibitor 1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem 1991; 266 : 2459-65.
27. Eriksson P, Kallin B, Van'tHoof FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92 : 1852-5.
28. Eriksson P, Reynisdottir S, Lonnqvist F, Stemme V, Hamsten A, Arner P. Adipose tissue secretion of plasminogen activator inhibitor 1 in non-obese and obese individuals. Diabetologia 1998; 41 : 65-71.
29. Feener EP, Northrup JM, Aiello LP, King GL. Angiotensin II induces plasminogen activator inhibitor 1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 1995; 95 : 1353-62.
30. Frayn KN. Insulin resistance and lipid metabolism. Curr Opin Lipidol 1993; 4 : 197-204.
31. Folsom AR, Qamhieh HK, Wing RR, Jeffrey RW, Stinson VL, Kuller LH, et al. Impact of weight loss on plasminogen activator inhibitor 1 (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb Vasc Biol 1993; 13 : 161-9.
32. Giltay EJ, Elbers JMH, Gooren LJG, Emeis JJ, Kooistra T, Asscheman H, et al. Visceral fat accumulation is an important determinant of PAI-1 levels in young, non obese men and women. Modulation by cross-sex hormone administration. Arterioscler Thromb Vasc Biol 1998; 18 : 1716-22.
33. Grant PJ, Kruithof EKO, Felley CP, Felber JP, Bachmann F. Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor 1 concentrations in man. Clin Sci 1990; 79 : 513-6.
34. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Eng J Med 1985; 31 : 1557-63.
35. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; 2 : 3-9.
36. Henry M, Chomiki N, Scarabin PY, Alessi MC, Peiretti F, Arveiler D, et al. Five frequent polymorphism of plasminogen activator inhibitor 1 gene: Lack of association between genotypes, PAI activity and triglycéride levels in a healthy population. Arterioscler Thromb Vasc Biol 1997; 17 : 851-8.
37. Hubert HB, Feinlieb MD, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the framingham study. Circulation 1983; 67 : 968-76.
38. Janand-Delenne B, Chagnaud C, Raccah D, Alessi MC, Juhan-Vague I, Vague P. Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. Int J Obesity 1998; 22 : 312-7.
39. Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non-insulin-dependent diabetic patients. Relationship with plasma insulin. Thromb Haemost 1989; 61 : 370-3.
40. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34 : 457-62.
41. Juhan-Vague I, Alessi MC, Nalbone G. Fibrinolysis and atherothrombosis. Curr Opin Lipidol 1993; 4 : 477-83.
42. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost 1993; 70 : 138-43.
43. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78 : 656-60.
44. Kato K, Satoh H, Endo Y, Yamada D, Midorikawa S, Sato W, et al. Thiazolidindiones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARγ in endothelial function. Biochem Biophys Res Commun 1999; 258 : 431-5.
45. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995; 96 : 2515-20.
46. Klinger KW, Winqvist R, Riccio A. Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis. Proc Natl Acad Sci USA 1987; 84 : 8548-52.
47. Kooistra T, Bosma PJ, Töns HAM, van den Berg AP, Meyer P, Princen HMG. Plasminogen activator inhibitor 1: Biosynthesis and mRna level are increased by insulin in cultured human hepatocytes. Thromb Haemost 1989; 62 : 723-8.
48. Kruithof EKO. Plasminogen activator inhibitor type 1 : Biochemical, biological and clinical aspects. Fibrinolysis 1988; 2 : 59-70.
49. Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor 1. Metabolism 1990; 39 : 1044-8.
50. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990; 227 : 273-8.
51. Landin K, Tengborn L, Chmielewska J, von ScHenk H, Smith U. The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man. Thromb Haemost 1991 : 65; 130-3.
52. Levi M, Biemond BJ, Van Zonneveld AJ, Ten Cate JW, Pannekoek H. Inhibition of plasminogen activator inhibitor 1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85 : 305-12.
53. Lijnen HR, Collen D. Mechanism of physiological fibrinolysis. Baillières Clin Haematol 1995; 8 : 277-90.
54. Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity. Studies of PAI-1. Arterioscler Thromb Vasc Biol 1998; 18 : 1-6.
55. Lundgren CH, Brown SL, Nordt TD, Sobel BE, Fijii S. Elaboration of type 1 plasminogen activator inhibitor from adipocytes. A potential link between obesity and cardiovascular disease. Circulation 1996; 93 : 106-10.
56. Mansfield MW, Strickland MH, Carter AM, Grant PJ. Polymorphisms of the plasminogen activator inhibitor 1 gene in type 1 and type 2 diabetes, and in patients with diabetic retinopathy. Thromb Haemost 1994; 71 : 731-6.
57. Mansfield MW, Stickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor 1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 1995; 74 : 842-7.
58. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J. PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARg as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 1999; 19 : 546-51.
59. Mavri A, Stegnar M, Krebs M, Sentocnick JT, Geiger M, Binder BR. Impact of adipose tissue on plasma plasminogen activator inhibitor 1 in dieting obese women. Arterioscler Thromb Vasc Biol 1999; 19 : 1582-7.
60. Morange PE, Alessi MC, Verdier D, Casanova G, Magalon G, Juhan-Vague I. PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level. Arterioscler Thromb Vasc Biol 1999; 19 : 1361-5.
61. Mussoni L, Maderna P, Camera M, Bernini F, Sironi L, Sirtori M, et al. Atherogenic lipoproteins and PAI-1 releases by endothelial cells. Fibrinolysis 1990; 4 Suppl 2 : 79-81.
62. Mussoni L, Mannucci L, Sirtori M, Camera M, Maderna P, Sironi L, et al. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb Vasc Biol 1992; 12 : 19-27.
63. Mykkänen L, Rönnemaa T, Marniemi J, Haffner SM, Bergman R, Laasko M. Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor 1 activity. Arterioscler Thromb Vasc Biol 1994; 14 : 1264-71.
64. Naito M, Funaki C, Hayashi T, Yamada K, Asai K, Yoshimine N, et al. Substrate-bound fibrinogen, fibrin and other cell attachment-promoting proteins as a scaffold for cultures vascular smooth muscle cells. Athersclerosis 1992; 96 : 227-34.
65. Nilsson L, Banfi C, Diczfalusy U, Tremoli E, Hamsten A, Eriksson P Unsaturated fatty acids increase plasminogen activator inhibitor 1 expression in endothelial cells. Arterioscler Thromb Vasc Biol 1998; 18 : 1679-85.
66. Olofsson BO, Dahlen G, Nilsson TK. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 1989; 10 : 77-82.
67. Padayatty SJ, Orme S, Zenobi PD, Stickland MH, Belchetz PE, Grant PJ. The effects of insulin-like growth factor-1 on plasminogen activator inhibitor 1 synthesis and secretion: Results from in vitro and in vivo studies. Thromb Haemostas 1993; 70 : 1009-13.
68. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995; 44 : 37-42.
69. Potter Van Loon BJ, de Bart ACW, Radder JK, Frouch M, Kluft C, Menders AE. Acute exogenous hyperinsulinaemia does not result in elevation of plasma plasminogen activator inhibitor 1 (PAI-1) in human. Fibrinolysis 1990; 4 : 93-4.
70. Potter Van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 1993 : 42 : 945-9.
71. Raccah D, Alessi MC, Scelles V, Menard C, Juhan-Vague I, Vague P. Plamsinogen activator inhibitor activity in various types of endogenous hypertriglyceridemia. Fibrinolysis 1993; 7 : 171-6.
72. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37 : 1595-607.
73. Reaven GM. Pathogenesis of insulin resistance in human disease. Physiol Rev 1995; 75 : 473-86.
74. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993; 87 : 1969-73.
75. Samad F, Yamamoto K, Lostkutoff DJ. Distribution and regulation of plasminogen activator inhibitor 1 in murine adipose tissue in vivo: Induction by tumor necrosis factor-α and lipopolysaccharide. J Clin Invest 1996; 97 : 37-46.
76. Samad F, Loskutoff DJ. Tissue distribution and regulation of plasminogen activator inhibitor 1 in obese mice. Mol Med 1996; 2 : 568-82.
77. Sawdey S, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor (PAI-1) gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor a and transforming growth factor-β. J Clin Invest 1991; 88 : 1346-53.
78. Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibiror type 1 by insulin and insulin-like growth factor type 1: Implications for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci USA 1991; 88 : 9959-63.
79. Schneider DJ, Nordt TK, Sobel BE. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes 1993; 42 : 1-7.
80. Schneider DJ, Absher PM, Ricci MA. Dependence of augmentation of arterial endothelial cell expression of plasminogen activator inhibitor type 1 by insulin on soluble factors released from vascular smooth muscle cells. Circulation 1997; 96 : 2868-76.
81. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, et al. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity. Nat Med 1996; 2 : 800-3.
82. Sitko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor 1 from cultured human umbilical vein endothelial cells induced by very low density lipoprotein. Arteriosclerosis 1990; 10 : 1067-73.
83. Smith EB, Cochran S. Factors influencing the accumulation in fibrous plaque of lipid derived from low density lipoprotein. Part II. Preferential immobilization of lipoprotein (a). Atherosclerosis 1990; 84 : 173-81.
84. Spiegelman BM. PPAR-γ: Adipogenic regulator and thiazolidindione receptor. Diabetes 1998; 47 : 507-14.
85. Svendsen OL, Hassger C, Christiansen C, Nielsen JD, Winther K. Plasminogen activator inhibitor 1, tissue-type plasminogen activator, and fibrinogen. Effect of dieting with or without exercise in overweight postmenopausal women. Arterioscler Thromb Vasc Biol 1996; 16 : 381-5.
86. Sylvan A, Rutergard JN, Janunger KG, Sjölund B, Nilsson TK. Normal plasminogen activator inhibitor levels at long-term follow-up after jejuno-ileal bypass in morbidly obese individuals. Metabolism 1992; 41 : 1370-2.
87. Thompson WD, Smith EB. Atherosclerosis and the coagulation system. J Pathol 1989; 159 : 97-106.
88. Toft I, Bonaa KH, Ingebretsen OC, Nordoy A, Birkeland KI, Jenssen T. Gender differences in the relationships between plasma plasminogen activator inhibitor 1 activity and factors linked to the insulin resistance syndrome in essential hypertension. Arterioscler Thromb Vasc Biol 1997; 17 : 553-9.
89. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 1986; 35 : 250-3.
90. Vague P, Juhan-Vague I, Chabert V, Alessi MC, Atlan C. Fat distribution and plasminogen activator inhibitor activity in non diabetic obese women. Metabolism 1989; 38 : 913-5.
91. Vague P, Raccah D, Scelles V. Hypofibrinolysis and the insulin resistance syndrome. Int J Obesity 1995; 19 Suppl 1 : S11-5.
92. Van Steenbergen W, Lanckmans S. Liver disturbances in obesity and diabetes mellitus. Int J Obesity 1995; 19 Suppl 3 : S27-36.
93. Van Meijer, M, Pannehoek, H. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: An update. Fibrinolysis 1995; 9 : 263-76.
94. Vaughan DE, Declerck PJ, Van Houtte E, De Mol M, Collen D. Reactivated recombinant plasminogen activator inhibitor 1 (rPai-1) effectively prevents thrombolysis in vivo. Thromb Haemost 1992; 68 : 60-3.
95. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor 1 in cultured endothelial cells: A potential link between the renin angiotensin system and thrombosis. J Clin Invest 1995; 95 : 995-1001.
96. Vuorinen-Markkola H, Puhakainen I, Yki-Järvinen H. No evidence for short-term regulation of plasminogen activator inhibitor activity by insulin in man. Thromb Haemost 1992; 67 : 117-20.
97. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors. Hepatology 1990; 12 : 1106-10.
98. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor 1 (PAI-1) associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemostas 1995; 74 : 837-41.